LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma | Zendy

Fengqin Hao | Zendy; Yanan Mou | Zendy; Laixia Zhang | Zendy; Shuna Wang | Zendy; Yang Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma

Author(s) -

Fengqin Hao,

Yanan Mou,

Laixia Zhang,

Shuna Wang,

Yang Yang

Publication year - 2018

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20180384

Subject(s) - retinoblastoma , cancer research , biology , cell cycle , cell growth , cell migration , retinoblastoma protein , cell , antisense rna , rna , gene , genetics

The actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) has been found to serve as an oncogenic long noncoding RNA (lncRNA) in most types of human cancer. The role of AFAP1-AS1 in retinoblastoma remains unknown. The purpose of the present study is to explore the clinical significance and biological function of AFAP1-AS1 in retinoblastoma. Levels of AFAP1-AS1 expression were measured in retinoblastoma tissues and cell lines. Loss-of-function study was performed to observe the effects of AFAP1-AS1 on retinoblastoma cell proliferation, cell cycle, migration, and invasion. In our results, AFAP1-AS1 expression was elevated in retinoblastoma tissues and cell lines, and associated with tumor size, choroidal invasion, and optic nerve invasion. Moreover, high expression of AFAP1-AS1 was an independent unfavorable prognostic factor in retinoblastoma patients. The experiment in vitro suggested down-regulation of AFAP1-AS1 inhibited retinoblastoma cell proliferation, migration and invasion, and blocked cell cycle. In conclusion, AFAP1-AS1 functions as an oncogenic lncRNA in retinoblastoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research